Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers

Diagnostic Pathology

Kenji Ishizuka¹  Yumi Oshiro²  Shohei Shimajiri³  Hiromi Iwasaki⁴  Yasushi Takamatsu⁵  Shigeto Kawauchi⁶  Morishige Takeshita⁷  Shoichi Kimura⁸  Yasuhito Mihashi⁸ 

[1] Department of Internal Medicine, Faculty of Medicine, Kagoshima University, Sakuragaoka 8-35-1, 890-8544, Kagoshima, Japan;Department of Pathology, Matsuyama Red Cross Hospital, 1 Bunkyo-cho, 791-0000, Matsuyama, Japan;Department of Pathology, University of Occupational and Environmental Health, Iseigaoko Yahata Nishi-ku, Kitakyushu, Japan;Departments of Haematology, Clinical Research Centre, National Hospital Organisation Kyushu Medical Centre, 1-8-1 Jigyohama, Chuo-ku, 810-8563, Fukuoka, Japan;Departments of Internal Medicine, Division of Medical Oncology, Haematology and Infectious Disease, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan;Departments of Pathology, Clinical Research Centre, National Hospital Organisation Kyushu Medical Centre, 1-8-1 Jigyohama, Chuo-ku, 810-8563, Fukuoka, Japan;Departments of Pathology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan;Departments of Pathology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan;Departments of Otolaryngology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan;

关键词: AITL;    CMYC;    PD-1;    PD-L1;    Peripheral T-cell lymphoma;    T follicular helper cell;   

DOI  :  10.1186/s13000-021-01163-7

来源: Springer

【 摘 要 】

BackgroundThe clinicopathological characteristics and prognostic factors in nodal peripheral T-cell lymphomas (PTCLs) with two or more T follicular helper markers (TFH+) are not adequately investigated.MethodsImmunohistologically, we selected 22 patients with TFH+ lymphoma (PTCL-TFH) in 47 of PTCL-not otherwise specified (NOS), and subclassified into large and small cell groups. We compared the two groups with 39 angioimmunoblastic T-cell lymphoma (AITL) and seven follicular T-cell lymphoma (F-TCL) patients. Prognostic factors were analysed by overall survival in patients with three types of TFH+ PTCLs.ResultsThirteen large cell and nine small cell PTCL-TFH patients had more than two TFH markers including programmed cell death-1 (PD-1). Large cell PTCL-TFH showed frequent CMYC expression in 10 patients (77%), and four of 11 large cell group (36%) had somatic RHOA G17V gene mutation by Sanger sequencing. Large cell PTCL-TFH patients showed significantly worse prognosis than those of the small cell group, AITL, and F-TCL (p < 0.05). In TFH+ PTCLs, CMYC+ tumour cells, and combined PD-1 ligand 1 (PD-L1) + tumour cells and intense reaction of PD-L1+ non-neoplastic cells (high PD-L1+ cell group) were significantly poor prognostic factors (p < 0.05). Combinations of CMYC+ or PD-1+ tumour cells and high PD-L1+ cell group indicated significantly poor prognosis (p < 0.01).ConclusionLarge cell PTCL-TFH indicated poor prognosis in TFH+ PTCLs. These data suggested that CMYC+ tumour cells and intense PD-L1+ cell reaction influenced tumour cell progression in TFH+ PTCLs, and PD-1+ tumour cell/intense PD-L1+ cell reactions may play a role in immune evasion.

【 授权许可】

CC BY